Articles tagged with Gliomas
A phase 3 clinical trial by Dana-Farber Cancer Institute has shown vorasidenib significantly prolongs progression-free survival and delays radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma. Treatment with vorasidenib can delay cognitive dysfunction in patients and preserve their quality of life.
A new targeted therapy drug vorasidenib has been shown to extend treatment time without worsening glioma in people with IDH1 and IDH2 mutations. The study suggests a possible new treatment option for slow-growing but deadly brain tumors, delaying chemotherapy and radiation.
Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...
Researchers at Cold Spring Harbor Laboratory have developed a potential therapeutic for diffuse intrinsic pontine glioma (DIPG) using antisense oligonucleotide technology. The treatment has slowed tumor growth, reversed changes in cancer cells, and increased survival rates in mice with DIPG.
Researchers developed an AI-based diagnostic screening system called DeepGlioma to analyze tumor specimens and detect genetic mutations rapidly. The system identified molecular subgroups with high accuracy and has the potential to improve access and speed of diagnosis for patients with deadly brain tumors.
Researchers identified high expression of glypican-1 in primary solid tumors, correlating with poor prognosis in various cancer types. Suppression of GPC1 attenuated cancer cell proliferation, suggesting its potential as a novel diagnostic tool and target for therapy.
A team of researchers at Baylor College of Medicine found that glioma-related epilepsy is driven by IGSF3-mediated potassium dysregulation. This disruption leads to seizure activity, which favors disease progression. The study used human patients and animal models to confirm the findings.
Researchers at Michigan Medicine discovered a gene, ZMYND8, that contributes to the survival of mutant IDH1 glioma cells in response to radiation. Knocking out ZMYND8 renders the cells radiosensitive, offering a new therapeutic avenue for patients.
Researchers tracked 392 patients with diffuse low-grade glioma over 20 years and found that aggressive surgical removal offered a distinct survival advantage. Smaller tumor sizes were associated with longer survival times, highlighting the importance of early intervention.
A new AI tool developed by Brigham and Women's Hospital improves the accuracy of time-critical pathology diagnostics during surgery. The tool, which leverages deep-learning technology, translates frozen tissue samples into high-quality images, increasing diagnostic accuracy and reducing the need for lengthy laboratory tests.
A study using spatial single-cell transcriptomics reveals the spatial organization of cancer cells in patient tissues across ages and locations. The research highlights age- and location-dependent differences in tumor biology, suggesting that kids and adults with diffuse midline gliomas may need different treatments.
Researchers developed a mouse model of pediatric glioma with a histone mutation called H3.3-G34, revealing a promising outlook for long-term survival through radiation therapy combined with small-molecule inhibitors. The treatment approach also showed immune memory, allowing mice to eliminate new tumor growth without additional treatment.
Advanced nanoparticles carrying a bacterially derived compound target the STING pathway, disrupting blood vessels and stimulating an immune response. This approach suppresses tumor growth and metastasis in several types of cancers.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.
Researchers discovered that animal models with germline alteration rs55705857 developed gliomas significantly faster than those without the alteration. The study offers new insights into tumor formation and may lead to novel therapies targeting this specific change.
A new study found that high-grade gliomas remodel the surrounding brain environment to protect tumour cells and hide them from the body's defences. Lower grade tumours often develop a new mutation allowing rapid cell division, potentially progressing to higher grade forms.
A multi-institutional team assessed the diagnostic criteria for canine glioma using the Comparative Brain Tumor Consortium's guidelines. The study found that consensus was achieved for 71 out of 85 cases (84%), with a moderate level of inter-pathologist agreement.
Researchers have developed an immunity-boosting postoperative treatment that could prevent glioblastoma relapse by targeting cancer stem cells with nanoparticles. The injectable gel promotes the cancer-killing immune response and reduces toxic side effects.
Researchers at Massachusetts General Hospital have developed a blood test that can detect multiple mutations associated with brain cancer, including EGFRvIII. The test showed high sensitivity and specificity, making it a powerful tool for diagnosing gliomas and monitoring tumor progression.
Updated long-term results from Phase III trials demonstrate significant benefits from combining procarbazine, lomustine, and vincristine chemotherapy with radiation therapy for patients with anaplastic oligodendrogliomas. Patients with chromosome 1p19q codeleted tumors experienced improved overall survival and progression-free survival.
Researchers at Michigan Medicine developed a nanoparticle-based inhibitor that successfully triggers the immune system to eliminate brain tumors in mouse models. The approach breaks the shield built by glioma cells around the immune system, allowing the immune cells to attack and delay tumor progression.
A study from the University of Pittsburgh found that methionine restriction can slow down the growth of difficult-to-treat brain tumors in children, known as diffuse midline gliomas. The researchers discovered that these tumors are uniquely dependent on methionine, an amino acid, and that depleting it can repress cancer cell growth.
Pediatric cancer patients from lower- and middle-income countries faced a higher risk of all-cause mortality than those in high-income countries during the COVID-19 pandemic. The study found that patients in LMICs had 35.7 times the risk of all-cause mortality compared to those in HICs.
Researchers discovered a novel mechanism for miR-10b activation in high-grade gliomas, implicating topologic reorganization of chromatin and long-non-coding RNAs. This finding suggests new RNA-targeted strategies for glioma therapy and points to the vulnerability of tumor-initiating cells.
Post-surgery patients exhibit moderate speech disorders affecting all language processing aspects, whereas post-stroke patients display specific phonological deficits. Understanding these differences is crucial for developing targeted therapies.
Researchers collected hundreds of cerebrospinal fluid samples from patients with Diffuse Midline Glioma, tracking changes in cell-free tumor DNA over time. The findings suggest that this method could provide data about tumors sooner than MRIs alone, allowing clinicians to address aggressive brain cancer more effectively.
A UC researcher is leading three projects to study the genetic workings of deadly pediatric brain tumors, including DIPG. The goal is to understand how genes regulate blood vessels and develop more effective treatments. Researchers are also exploring a new drug that targets a specific genetic mutation.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
Research reveals that the parietooccipital fissure acts as an obstacle to glioma invasion, with tumor cells making a detour around it. This finding highlights the importance of this fissure in determining the invasion pattern of posterior medial temporal gliomas.
Researchers found that asthma causes immune cells to behave in a way that prevents brain tumor growth, suggesting a potential new therapeutic approach. The findings suggest reprogramming T cells to act like those in asthma patients could be a new treatment for brain tumors.
Researchers have found a small-molecule inhibitor that can suppress tumor growth in animal models of H3.3G34R/V glioma, offering new treatment options for pediatric patients. The compound has the potential to cross the blood-brain barrier and is currently being tested in clinical trials.
Researchers at Weill Cornell Medicine have profiled individual cells from patients' brain tumors in unprecedented detail, revealing distinct states and programming marks that could be targeted with future drugs. The study offers insights into glioma dynamics and may lead to better detection, staging, monitoring, and treatment methods.
Researchers have identified a common mutation in gliomas that sensitizes them to immunotherapy, which can lead to improved survival rates and tumor-free periods. The discovery may have broader therapeutic implications for all glioma patients, offering new hope for treatment.
Pediatric oncologist Adam Green and his team have discovered genetic mutations that may predict the development of these secondary tumors, allowing for early detection and alternative treatments. They are also exploring FDA-approved chemotherapy drugs as potential treatments.
Researchers discovered that new mutations in the BRAF gene can lead to gliomas growing back after treatment, suggesting personalized approaches to therapy. The study also explored potential impacts of COVID-19 vaccines on menstruation.
A team of researchers led by CU Cancer Center member Jean Mulcahy Levy examined tumor samples before and after treatment with a targeted medicine. They found additional mutations that can create resistance to the therapy, highlighting the need for new treatments or combination therapies.
A new study suggests that a treatment for canine glioblastoma may also be effective in humans, with some dogs experiencing significant tumor shrinkage. The treatment uses an immunotherapy drug called STING agonist, which induced a robust immune response against cancer cells.
A study by the Center for Cell-Based Therapy in São Paulo, Brazil, has discovered a set of biomarkers that can be used to predict which patients with glioblastoma may have tumors resistant to radiation therapy. The genetic signature helps doctors choose the best treatment option for these patients.
A new study reveals that high-grade gliomas in dogs contain more immune cells associated with suppressing immune response than low-grade gliomas. The findings suggest that these brain tumors may recruit cells to aid in immunosuppression, which could lead to improved immunotherapies for both humans and dogs.
The study confirms the upregulation of TERT in primary glioblastomas and the gradual expression of all GABP components during malignancy progression. The authors found a positive association between TERT and B1L mRNA expression, highlighting the importance of GABPA/B isoforms in mutated TERT promoter-dependent gliomas.
Researchers discovered that neural activity underlying visual signals can ignite and feed tumors in young children with neurofibromatosis type 1. The study found that raising mice in the dark or treating them with an experimental cancer drug slowed tumor growth, suggesting a key role for controlling neuronal activity.
Scientists discover a way to reactivate paralyzed immune cells against IDH-mutant gliomas, leading to improved vaccine effectiveness. The researchers identified the molecular mechanism behind the 'immune paralysis' caused by cancer-promoting metabolic products and found a substance that deactivates a key immune system regulatory molecule.
Researchers found that female mice with glioma lacking the POT1 gene survived less than males, leading to further investigation of human glioma cells. Low POT1 expression correlated with reduced survival in females, suggesting immune response and tumor cell proliferation played a role in tumor growth.
A clinical trial tested a mutation-specific vaccine against IDH1-mutated gliomas, a type of diffuse brain tumor. The vaccine proved safe and triggered the desired immune response in 93% of patients, with some experiencing pseudoprogression and tumor growth slowing.
A novel gene therapy has been developed to convert glioma cells into functional neurons, offering a new approach to treating the disease. This technology may prolong treatment time by arresting rapid proliferation of malignant glioma cells.
A new glioma-targeted nano-therapeutic developed by UH researcher Sheereen Majd delivers the highly toxic anti-cancer drug Dp44mT directly to brain tumor cells, reducing toxicity and improving treatment outcomes.
A novel combination treatment approach has shown encouraging results in mice with tumors similar to human astrocytomas. The treatment, which blocks D-2-HG production and inhibits an immune checkpoint protein, led to tumor regression in 60% of treated animals, improving survival rates.
Researchers developed a new method to classify brain tumors using RNA analysis, achieving high accuracy rates compared to traditional methods. The study found that this approach can identify patients with a worse prognosis and detect secondary glioblastomas not detected by other methods.
A new study suggests a link between Toxoplasma gondii infection and the risk of glioma, a type of brain cancer, in adults. Researchers found that people with glioma were more likely to have antibodies to T.gondii than those without the disease.
Researchers have developed a portable DNA sequencing technology to detect tumor DNA in cerebrospinal fluid, allowing for rapid and reliable monitoring of high-grade gliomas. This approach overcomes traditional barriers to diagnosing and treating pediatric brain cancer, offering a non-invasive alternative to invasive surgeries.
Researchers at Massachusetts General Hospital have developed a non-invasive liquid biopsy test that can detect genetic mutations in brain tumor patients. The test, which improved detection sensitivity by tenfold, has the potential to revolutionize glioma diagnosis and monitoring.
Researchers at FEFU are working on genetically modified models of brain tumors to understand the role of IDH1 and TP53 gene mutations. They plan to create laboratory models of these mutations to develop new diagnostic markers and test antitumor compounds, potentially leading to personalized therapy for glioma patients.
A research team from CNIO and HKUST has discovered a specific genetic alteration in some glioma patients that evades the combined therapy, leading to resistance. The study provides clues on how to monitor therapy efficacy and may lead to changes in treatment methods.
Researchers have identified a promising new strategy to target tumors with metabolic weaknesses, particularly in patients with IDH mutant gliomas. Combining chemotherapy and PAR glycohydrolase inhibitors has shown promise in enhancing treatment effectiveness.
A new machine learning approach classifies gliomas into low or high grades with near-perfect accuracy, enabling clinicians to choose the most effective treatment strategy. Researchers developed the method using MRI scans from over 200 patients and achieved an accuracy rate of 97.54%, outperforming state-of-the-art approaches.
A new study uses AI to identify a specific genetic mutation in glioma tumors, achieved with over 97% accuracy. The technology could simplify the process of detecting enzyme mutations and deciding on appropriate therapy, potentially revolutionizing brain cancer treatment.
A study published in Nature found that glioma patients with hypermutated tumor cells did not benefit from checkpoint blocker treatments. The researchers suggest that approaches increasing cytotoxic lymphocyte infiltration may improve immunotherapy response in gliomas.
A new study has identified a potent Nrf2 inhibitor, triptolide, as a promising therapeutic approach for IDH1-mutated glioma. The research reveals that disrupting the glutathione synthesis pathway establishes synergistic lethality with a neomorphic IDH1 mutation.
A recent study published in Neuro-Oncology has made significant progress in understanding low-grade gliomas (LGG) in NF patients, which affect nearly a third of those with NF1. The research collaboration between NF experts and LGG specialists aims to develop new therapeutic strategies for these patients.